Data / Form D filings / NORMOXYS, INC.
NORMOXYS, INC.: Form D filings
NORMOXYS, INC., a biotechnology company in Boston, MA, filed 5 Form D notices with the SEC between 2009 and 2011. The latest, on November 21, 2011, reports $600,000 sold of a $1.1 million offering to 6 investors.
Find out what NORMOXYS, INC. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 300 Market Street, Boston, MA, 02135
- Phone
- (617) 719-9489
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506
- SEC identifier (CIK)
- 1411024
The full lists. Form D filings in Massachusetts: 1,533 rows, $76.65, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Nov 21, 2011 | New notice | $1,100,000 | $600,000 | $500,000 | 6 | Nov 7, 2011 | sec.gov |
| Jun 23, 2011 | New notice | $1,687,587 | $1,556,353 | $131,234 | 13 | Jun 10, 2011 | sec.gov |
| May 25, 2010 | New notice | $17,564,384 | $17,564,384 | $0 | 15 | May 10, 2010 | sec.gov |
| Mar 24, 2010 | New notice | $1,050,000 | $1,050,000 | $0 | 7 | Mar 21, 2010 | sec.gov |
| Apr 29, 2009 | New notice | $4,506,708 | $4,506,708 | $0 | 5 | Apr 22, 2009 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| FRANCESCO DE RUBERTIS | Director | |
| MARTIN TOLAR | Executive Officer, Director | |
| ARGERIS KARABELAS | Director | |
| MICHELE OLLIER | Director | |
| CONRAD BLETZER, JR. | Executive Officer | |
| JEAN-PIERRE GARNIER | Director | |
| CLAUDE NICOLAU | Director |
Other biotechnology companies in Massachusetts that filed recently
- Zai Lab Ltd $249.9 million · Nov 9, 2026
- AI3 Bio, Inc. offering · Nov 4, 2026
- Tru Singular Health, Inc. $1 million · Oct 30, 2026
- 511 Therapeutics, Inc. $500,000 · Oct 30, 2026
- Elucid Bioimaging Inc. $56.2 million · Oct 27, 2026
- OrthoIQ, Inc. $1.1 million · Oct 23, 2026
- LeanBio Therapeutics, Inc. offering · Oct 22, 2026
- Quiver Holdings Inc. $3 million · Oct 21, 2026
- Axelyf, Inc. $2.6 million · Oct 13, 2026
- BIOVENTRIX, INC. $1.2 million · Oct 8, 2026
- Opus KSD, Inc. $680,801 · Oct 1, 2026
- Xact Bio, Inc. $10 million · Sep 28, 2026
- Way Biosolutions, Inc. $2 million · Sep 25, 2026
- AutoIVF, Inc. $1.5 million · Sep 25, 2026
- Typewriter Therapeutics, Inc. $56.3 million · Sep 21, 2026
Every Form D from the week of Nov 21, 2011 · All recent filings in Massachusetts · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what NORMOXYS, INC. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.